The latter genetic disorder is caused by PTPN11 gain of function mutations, whereas the clinically similar LEOPARD Syndrome is linked to mutations reducing the catalytic activity of SHP-2. This evidence concerns the gene PTPN11 and Noonan syndrome with multiple lentigines.